<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GRANISETRON HYDROCHLORIDE - granisetron hydrochloride injection </strong><br>WOCKHARDT LIMITED<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use granisetron hydrochloride injection safely and effectively. See full prescribing information for granisetron hydrochloride injection.<br><br>Granisetron Hydrochloride Injection, USP, for intravenous use<br><br>Initial U.S. Approval: 1993</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>Granisetron hydrochloride injection, USP  is a serotonin-3 (5-HT<span class="Sub">3</span>) receptor antagonist indicated for:<br><ul><li>Prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. (1)</li></ul>
<br>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<span class="Underline">Prevention of chemotherapy-induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2.1):</span><ul>
<li>Recommended dosage is 10 mcg/kg intravenously within 30 minutes before initiation of chemotherapy</li>
<li>Pediatric patients (2 to 16 years): Recommended dosage is 10 mcg/kg</li>
</ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<br><ul><li>Injection 1 mg/mL (free base). (3)</li></ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<br><ul><li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to granisetron or to any of its components. (4)</li></ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Granisetron hydrochloride injection does not stimulate gastric or intestinal peristalsis and should not be used instead of nasogastric suction. (5.1)</li>
<li>QT prolongation has been reported with granisetron hydrochloride injection. Use with caution in patients with pre-existing <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> or cardiac conduction disorders. (5.2)     </li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, may occur in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other selective 5-HT<span class="Sub">3</span> receptor antagonists. (5.3)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>Most common adverse reactions:<br><ul><li>Chemotherapy-induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (≥3%): <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (6.1)</li></ul>
<br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Wockhardt USA LLC. at 1-800-346-6854 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.<br></span><br>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Granisetron hydrochloride injection has been administered safely with benzodiazepines, neuroleptics, and anti-<span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> medications. (7)</li>
<li>Does not appear to interact with emetogenic cancer chemotherapies. (7) </li>
<li>Inducers or inhibitors of CYP450 enzymes may change the clearance and therefore the half-life of granisetron. (7)</li>
<li>Coadministration of granisetron hydrochloride injection with drugs known to prolong the QT interval and/or are arrhythmogenic may result in clinical consequences. (7)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy: Use only if clearly needed. (8.1)</li>
<li>Nursing mothers: Caution should be exercised when administered to a nursing woman. (8.3)</li>
<li>Geriatric use: No differences in responses between the elderly and younger patients were observed in reported clinical experience. (8.5)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Prevention of Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Gastric or Intestinal Peristalsis</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Cardiovascular Events</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>Granisetron hydrochloride injection is a serotonin-3 (5-HT<span class="Sub">3</span>) receptor antagonist indicated for:<br><ul><li>The prevention of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin.</li></ul>
<br>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="c2eb41d6-6dfa-40c8-8cb3-7198daf66d49"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<br><div class="Section" data-sectionCode="34068-7">
<a name="section-2.1"></a><p></p>
<h2>2.1 Prevention of Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></h2>
<span class="Underline">Adult Patients</span><br>The recommended dosage for granisetron hydrochloride injection is 10 mcg/kg administered intravenously within 30 minutes before initiation of chemotherapy, and only on the day(s) chemotherapy is given.<br><br><span class="Underline">Infusion Preparation</span><br>Granisetron hydrochloride injection may be administered intravenously either undiluted over 30 seconds, or diluted with 0.9% Sodium Chloride or 5% Dextrose and infused over 5 minutes.<br><br><span class="Italics">Stability</span><br>Intravenous infusion of granisetron hydrochloride injection should be prepared at the time of administration. However, granisetron hydrochloride injection has been shown to be stable for at least 24 hours when diluted in 0.9% Sodium Chloride or 5% Dextrose and stored at room temperature under normal lighting conditions.<br><br>As a general precaution, granisetron hydrochloride injection should not be mixed in solution with other drugs. Parenteral drug products should be inspected visually for particulate matter and discoloration before administration whenever solution and container permit.<br><br><span class="Underline">Pediatric Patients</span><br>The recommended dose in pediatric patients 2 to 16 years of age is 10 mcg/kg <span class="Italics">[see Clinical Studies (14)].</span> Pediatric patients under 2 years of age have not been studied.<br>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="cc777f76-cbe1-42ae-b9d3-dc3260ebb82a"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>Multi-Use Vials for Injection: 4 mg/4mL<br>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="a578b70d-83ee-4a31-9058-f9f2c9201604"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>Granisetron hydrochloride injection is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (eg. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>) to the drug or to any of its components.<br>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="fb8745e7-6218-4486-a850-1d64c486e931"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5.1"></a><p></p>
<h2>5.1 Gastric or Intestinal Peristalsis</h2>Granisetron hydrochloride injection is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of granisetron hydrochloride injection in patients following abdominal surgery or in patients with chemotherapy-induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may mask a progressive <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span> and/or gastric <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>.</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5.2"></a><p></p>
<h2>5.2 Cardiovascular Events</h2>An adequate QT assessment has not been conducted, but QT prolongation has been reported with granisetron hydrochloride injection. Therefore, granisetron hydrochloride injection should be used with caution in patients with pre-existing <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> or cardiac conduction disorders, as this might lead to clinical consequences. Patients with cardiac disease, on cardio-toxic chemotherapy, with concomitant electrolyte abnormalities and/or on concomitant medications that prolong the QT interval are particularly at risk.<br>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> (eg. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>) may occur in patients who have exhibited <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other selective 5-HT<span class="Sub">3</span> receptor antagonists.<br>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="a3a723ae-bf52-484c-807b-8756176b149c"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<br>QT prolongation has been reported with granisetron hydrochloride injection <span class="Italics">[see Warnings and Precautions (5.2) and Drug Interactions (7)].</span><div class="Section" data-sectionCode="34084-4">
<a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in patients.<br><br><span class="Underline">Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span><br>The following have been reported during controlled clinical trials or in the routine management of patients. The percentage figures are based on clinical trial experience only. Table 1 gives the comparative frequencies of the two most commonly reported adverse reactions (≥3%) in patients receiving granisetron hydrochloride injection, in single-day chemotherapy trials. These patients received chemotherapy, primarily cisplatin, and intravenous fluids during the 24-hour period following granisetron hydrochloride injection administration. Reactions were generally recorded over seven days post-granisetron hydrochloride injection administration.<br><br><a name="table1"></a><table width="80%">
<caption><span>Table 1  Principal Adverse Reactions in Clinical Trials-Single-Day Chemotherapy</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead>
<tr class="Botrule First">
<th class="Lrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">Percent of Patients With Reaction</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th class="Lrule Rrule" align="center">Granisetron Hydrochloride Injection<br>40 mcg/kg<br>(n=1268)</th>
<th class="Rrule" align="center">Comparator<span class="Sup">1</span><br><br>(n=422)</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule Rrule" align="center">14%</td>
<td class="Rrule" align="center">6%</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Lrule Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
</tr>
</tbody>
</table>
<span class="Sup">1</span>Metoclopramide/dexamethasone and phenothiazines/ dexamethasone. <br><br>Additional adverse events reported in clinical trials were <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.<br><br>In over 3,000 patients receiving granisetron hydrochloride injection (2 to 160 mcg/kg) in single-day and multiple-day clinical trials with emetogenic cancer therapies, adverse events, other than those adverse reactions listed in Table 1, were observed; attribution of many of these events to granisetron hydrochloride injection is uncertain.<br><br><span class="Italics">Hepatic:</span> In comparative trials, mainly with cisplatin regimens, elevations of AST and ALT (&gt;2 times the upper limit of normal) following administration of granisetron hydrochloride injection occurred in 2.8% and 3.3% of patients, respectively. These frequencies were not significantly different from those seen with comparators (AST: 2.1%; ALT: 2.4%).<br><span class="Italics"><br>Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> (2%); <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> such as <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, varying degrees of A-V block, ventricular ectopy including non-sustained <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and ECG abnormalities have been observed rarely.<br><br><span class="Italics">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, CNS stimulation and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> were seen in less than 2% of patients. <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal syndrome</span> occurred rarely and only in the presence of other drugs associated with this syndrome. <br><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> Rare cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, sometimes severe (eg, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>) have been reported.<br><br><span class="Italics">Other:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> (3%), taste disorder (2%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> (1%). In multiple-day comparative studies, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> occurred more frequently with granisetron hydrochloride injection (8.6%) than with comparative drugs (3.4%, P&lt;0.014), which usually included dexamethasone.<br><br>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>The following adverse reactions have been identified during post approval use of granisetron hydrochloride injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to granisetron hydrochloride injection exposure.<br><br>QT prolongation has been reported with granisetron hydrochloride injection <span class="Italics">[see Warnings and Precautions (5.2) and Drug Interactions (7)].</span>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="f302ed01-c5ba-42bc-bdba-7c89a1e10082"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>Granisetron does not induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system <span class="Italics">in vitro</span>. There have been no definitive drug-drug interaction studies to examine pharmacokinetic or <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interaction</span> with other drugs; however, in humans, granisetron hydrochloride injection has been safely administered with drugs representing benzodiazepines, neuroleptics and anti-<span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> medications commonly prescribed with antiemetic treatments. Granisetron hydrochloride injection also does not appear to interact with emetogenic cancer chemotherapies. Because granisetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of granisetron. No specific interaction studies have been conducted in anesthetized patients. In addition, the activity of the cytochrome P-450 subfamily 3A4 (involved in the metabolism of some of the main narcotic analgesic agents) is not modified by granisetron hydrochloride injection <span class="Italics">in vitro</span>. <br><br>In <span class="Italics">in vitro</span> human microsomal studies, ketoconazole inhibited ring oxidation of granisetron hydrochloride injection. However, the clinical significance of <span class="Italics">in vivo</span> <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> with ketoconazole is not known. In a human pharmacokinetic study, hepatic enzyme induction with phenobarbital resulted in a 25% increase in total plasma clearance of intravenous granisetron hydrochloride injection. The clinical significance of this change is not known. <br><br>QT prolongation has been reported with granisetron hydrochloride injection. Use of granisetron hydrochloride injection in patients concurrently treated with drugs known to prolong the QT interval and/or are arrhythmogenic may result in clinical consequences.</div>
<div class="Section" data-sectionCode="43684-0">
<a name="d6b98d98-68c2-4593-a58f-291c94669140"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<br><div class="Section" data-sectionCode="43684-0">
<a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<span class="Bold">Pregnancy Category B</span><br>Reproduction studies have been performed in pregnant rats at intravenous doses up to 9 mg/kg/day (54 mg/m<span class="Sup">2</span>/day, 146 times the recommended human dose based on body surface area) and pregnant rabbits at intravenous doses up to 3 mg/kg/day (35.4 mg/m<span class="Sup">2</span>/day, 96 times the recommended human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to granisetron. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether granisetron is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when granisetron hydrochloride injection is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"><span class="Underline">Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span><br><span class="Italics">[See Dosage and Administration (2)]  </span>for use in chemotherapy-induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in pediatric patients 2 to 16 years of age. Safety and effectiveness in pediatric patients under 2 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>During chemotherapy clinical trials, 713 patients 65 years of age or older received granisetron hydrochloride injection. The safety and effectiveness were similar in patients of various ages.</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="fa435aa3-c464-4af5-84a1-45dd38e72804"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>There is no specific antidote for granisetron hydrochloride injection overdosage. In case of overdosage, symptomatic treatment should be given. Overdosage of up to 38.5 mg of granisetron hydrochloride injection has been reported without symptoms or only the occurrence of a slight <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</div>
<div class="Section" data-sectionCode="34089-3">
<a name="b6037603-870c-4d43-8008-14cb36abd8a4"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>Granisetron hydrochloride injection, USP is a serotonin-3 (5-HT<span class="Sub">3</span>) receptor antagonist. Chemically it is <span class="Italics">endo</span>-N-(9-methyl-9-azabicyclo [3.3.1] non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride with a molecular weight of 348.9 (312.4 free base). Its empirical formula is C<span class="Sub">18</span>H<span class="Sub">24</span>N<span class="Sub">4</span>O•Hcl, while its chemical structure is:<br><div class="Figure"><img alt="Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=af68579f-c863-4535-94af-a4126b43c182&amp;name=granisetron.jpg"></div>Granisetron hydrochloride is a white crystalline powder, freely soluble in water and normal saline at 20°C. Granisetron hydrochloride injection, USP is a clear, colorless, sterile, nonpyrogenic, aqueous solution for intravenous administration.<br><br>Granisetron hydrochloride injection, USP 1 mg/mL is available in a 4 mL multi-use vial.<br><br>1 mg/ mL: Each mL contains 1.12 mg granisetron hydrochloride equivalent to granisetron, 1 mg; sodium chloride, 9 mg; citric acid, 2 mg; methylparaben, 1.8 mg; propylparaben, 0.2 mg; as a preservative and sodium hydroxide and hydrochloric acid (used to adjust pH). The solution's pH ranges from 4.0 to 6.0.</div>
<div class="Section" data-sectionCode="34090-1">
<a name="f41917fd-d344-449f-b7cb-6f03ac84369e"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<br><div class="Section" data-sectionCode="34090-1">
<a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>Granisetron is a selective 5-hydroxytryptamine<span class="Sub">3</span> (5-HT<span class="Sub">3</span>) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT<span class="Sub">1</span>; 5-HT<span class="Sub">1A</span>; 5-HT<span class="Sub">1B/C</span>; 5-HT<span class="Sub">2</span>; for alpha<span class="Sub">1</span>-, alpha<span class="Sub">2</span>- or beta-adrenoreceptors; for dopamine-D<span class="Sub">2</span>; or for histamine-H<span class="Sub">1</span>; benzodiazepine; picrotoxin or opioid receptors.<br><br>Serotonin receptors of the 5-HT<span class="Sub">3</span> type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy-induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT<span class="Sub">3</span> receptors. This evokes vagal afferent discharge and may induce <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Animal studies demonstrate that, in binding to 5-HT<span class="Sub">3</span> receptors, Granisetron blocks serotonin stimulation and subsequent <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> after emetogenic stimuli such as cisplatin. In the ferret animal model, a single granisetron injection prevented <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> due to high-dose cisplatin or arrested <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> within 5 to 30 seconds.<br><br>In most human studies, granisetron has had little effect on blood pressure, heart rate or ECG. No evidence of an effect on plasma prolactin or aldosterone concentrations has been found in other studies.<br><br>Granisetron hydrochloride injection exhibited no effect on oro-cecal transit time in normal volunteers given a single intravenous infusion of 50 mcg/kg or 200 mcg/kg. Single and multiple oral doses slowed colonic transit in normal volunteers.</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<span class="Bold">Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span><br>In adult cancer patients undergoing chemotherapy and in volunteers, mean pharmacokinetic data obtained from an infusion of a single 40 mcg/kg dose of granisetron hydrochloride injection are shown in Table 2.<br><a name="table3"></a><table width="90%">
<caption><span>Table 2  Pharmacokinetic Parameters in Adult Cancer Patients Undergoing Chemotherapy and in Volunteers, Following a Single Intravenous 40 mcg/kg Dose of Granisetron Hydrochloride Injection</span></caption>
<col align="left" valign="top" width="23%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="23%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="18%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Peak Plasma Concentration<br>(ng/mL)</th>
<th class="Rrule" align="center">Terminal Phase Plasma Half-Life<br>(h)</th>
<th class="Rrule" align="center">Total Clearance<br>(L/h/kg)</th>
<th class="Rrule" align="center">Volume of Distribution<br>(L/kg)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold">Cancer Patients</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Mean</td>
<td class="Rrule" align="center">63.8*
                                       </td>
<td class="Rrule" align="center">8.95*
                                       </td>
<td class="Rrule" align="center">0.38*
                                       </td>
<td class="Rrule" align="center">3.07*
                                       </td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Range</td>
<td class="Rrule" align="center">18.0 to 176</td>
<td class="Rrule" align="center">0.90 to 31.1</td>
<td class="Rrule" align="center">0.14 to 1.54</td>
<td class="Rrule" align="center">0.85 to 10.4</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">Volunteers</span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  21 to 42 years</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Mean</td>
<td class="Rrule" align="center">64.3<span class="Sup">†</span>
</td>
<td class="Rrule" align="center">4.91<span class="Sup">†</span>
</td>
<td class="Rrule" align="center">0.79<span class="Sup">†</span>
</td>
<td class="Rrule" align="center">3.04<span class="Sup">†</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Range</td>
<td class="Rrule" align="center">11.2 to 182</td>
<td class="Rrule" align="center">0.88 to 15.2</td>
<td class="Rrule" align="center">0.20 to 2.56</td>
<td class="Rrule" align="center">1.68 to 6.13</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  65 to 81 years</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Mean</td>
<td class="Rrule" align="center">57.0<span class="Sup">†</span>
</td>
<td class="Rrule" align="center">7.69<span class="Sup">†</span>
</td>
<td class="Rrule" align="center">0.44<span class="Sup">†</span>
</td>
<td class="Rrule" align="center">3.97<span class="Sup">†</span>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Range</td>
<td class="Rrule" align="center">14.6 to 153</td>
<td class="Rrule" align="center">2.65 to 17.7</td>
<td class="Rrule" align="center">0.17 to 1.06</td>
<td class="Rrule" align="center">1.75 to 7.01</td>
</tr>
</tbody>
</table>*5-minute infusion.<br><span class="Sup">†</span>3- minute infusion.<br><span class="Underline"><br>Distribution</span><br>Plasma protein binding is approximately 65% and granisetron distributes freely between plasma and red blood cells.<br><br><span class="Underline">Metabolism</span><br>Granisetron metabolism involves N-demethylation and aromatic ring oxidation followed by conjugation. <span class="Italics">In vitro</span> liver microsomal studies show that granisetron's major route of metabolism is inhibited by ketoconazole, suggestive of metabolism mediated by the cytochrome P-450 3A subfamily. Animal studies suggest that some of the metabolites may also have 5-HT<span class="Sub">3</span> receptor antagonist activity.<br><br><span class="Underline">Elimination</span><br>Clearance is predominantly by hepatic metabolism. In normal volunteers, approximately 12% of the administered dose is eliminated unchanged in the urine in 48 hours. The remainder of the dose is excreted as metabolites, 49% in the urine, and 34% in the feces.<br><span class="Underline"><br>Subpopulations</span><br><br><span class="Italics">Gender</span><br>There was high inter- and intra-subject variability noted in these studies. No difference in mean AUC was found between males and females, although males had a higher C<span class="Sub">max</span> generally.<br><span class="Italics"><br>Elderly</span><br>The ranges of the pharmacokinetic parameters in elderly volunteers (mean age 71 years), given a single 40 mcg/kg intravenous dose of granisetron hydrochloride injection, were generally similar to those in younger healthy volunteers; mean values were lower for clearance and longer for half-life in the elderly patients (see Table 2).<br><br><span class="Italics">Pediatric Patients</span><br>A pharmacokinetic study in pediatric cancer patients (2 to 16 years of age), given a single 40 mcg/kg intravenous dose of granisetron hydrochloride injection, showed that volume of distribution and total clearance increased with age. No relationship with age was observed for peak plasma concentration or terminal phase plasma half-life. When volume of distribution and total clearance are adjusted for body weight, the pharmacokinetics of granisetron are similar in pediatric and adult cancer patients.<br><span class="Italics"><br><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span> Patients</span><br>Total clearance of granisetron was not affected in patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> who received a single 40 mcg/kg intravenous dose of granisetron hydrochloride injection.<br><br><span class="Italics">Hepatically Impaired Patients</span><br>A pharmacokinetic study in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> due to neoplastic liver involvement showed that total clearance was approximately halved compared to patients without <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Given the wide variability in pharmacokinetic parameters noted in patients, dosage adjustment in patients with hepatic functional impairment is not necessary.<br>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ec9c4f81-5593-4084-87ec-8f3d32d2f375"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<br><div class="Section" data-sectionCode="43680-8">
<a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>In a 24-month carcinogenicity study, rats were treated orally with granisetron 1, 5 or 50 mg/kg/day (6, 30 or 300 mg/m<span class="Sup">2</span>/day). The 50 mg/kg/day dose was reduced to 25 mg/kg/day (150 mg/m<span class="Sup">2</span>/day) during week 59 due to toxicity. For a 50 kg person of average height (1.46 m<span class="Sup">2</span> body surface area), these doses represent 16, 81 and 405 times the recommended clinical dose (0.37 mg/m<span class="Sup">2</span>, iv) on a body surface area basis. There was a statistically significant increase in the incidence of hepatocellular carcinomas and <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in males treated with 5 mg/kg/day (30 mg/m<span class="Sup">2</span>/day, 81 times the recommended human dose based on body surface area) and above, and in females treated with 25 mg/kg/day (150 mg/m<span class="Sup">2</span>/day, 405 times the recommended human dose based on body surface area). No increase in <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> was observed at a dose of 1 mg/kg/day (6 mg/m<span class="Sup">2</span>/day, 16 times the recommended human dose based on body surface area) in males and 5 mg/kg/day (30 mg/m<span class="Sup">2</span>/day, 81 times the recommended human dose based on body surface area) in females. In a 12-month oral toxicity study, treatment with granisetron 100 mg/kg/day (600 mg/m<span class="Sup">2</span>/day, 1622 times the recommended human dose based on body surface area) produced <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> in male and female rats while no such tumors were found in the control rats. A 24-month mouse carcinogenicity study of granisetron did not show a statistically significant increase in tumor incidence, but the study was not conclusive.<br><br>Because of the tumor findings in rat studies, granisetron hydrochloride injection should be prescribed only at the dose and for the indication recommended <span class="Italics">[see Indications and Usage (1) and Dosage and Administration (2)].</span><br><br>Granisetron was not mutagenic in an <span class="Italics">in vitro</span> Ames test and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell forward mutation assay, and <span class="Italics">in vivo</span> mouse micronucleus test and <span class="Italics">in vitro</span> and <span class="Italics">ex vivo</span> rat hepatocyte UDS assays. It, however, produced a significant increase in UDS in HeLa cells <span class="Italics">in vitro</span> and a significant increased incidence of cells with polyploidy in an <span class="Italics">in vitro</span> human lymphocyte chromosomal aberration test.<br><br>Granisetron at subcutaneous doses up to 6 mg/kg/day (36 mg/m<span class="Sup">2</span>/day, 97 times the recommended human dose based on body surface area) was found to have no effect on fertility and reproductive performance of male and female rats.<br><br>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="e55bd685-08c5-4953-a129-19fac3c2c0f0"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<br><div class="Section" data-sectionCode="34092-7">
<a name="section-13.1"></a><p></p>
<h2>14.1 Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></h2>
<span class="Underline">Single-Day Chemotherapy<br></span><span class="Italics">Cisplatin-Based Chemotherapy</span><br>In a double-blind, placebo-controlled study in 28 cancer patients, granisetron hydrochloride injection, administered as a single intravenous infusion of 40 mcg/kg, was significantly more effective than placebo in preventing <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> induced by cisplatin chemotherapy (see Table 3).<br><br><a name="table5"></a><table width="75%">
<caption><span>Table 3  Prevention of Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>-Single-Day Cisplatin Therapy<span class="Sup">1</span></span></caption>
<col align="left" valign="top" width="45%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="18%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Granisetron Hydrochloride Injection</th>
<th class="Rrule" align="center">Placebo</th>
<th class="Rrule" align="center">P-Value</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">Number of Patients</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Response Over 24 Hours</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Complete Response<span class="Sup">2</span>
</td>
<td class="Rrule" align="center">93%</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">93%</td>
<td class="Rrule" align="center">14%</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">No More Than Mild <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">93%</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
</tbody>
</table>
<span class="Sup">1</span>Cisplatin administration began within 10 minutes of granisetron hydrochloride injection infusion and continued for 1.5 to 3.0 hours. Mean cisplatin dose was 86 mg/m<span class="Sup">2</span> in the granisetron hydrochloride injection group and 80 mg/m<span class="Sup">2</span> in the placebo group. <br><span class="Sup">2</span>No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and no moderate or severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. <br><br>Granisetron hydrochloride injection was also evaluated in a randomized dose response study of cancer patients receiving cisplatin ≥75 mg/m<span class="Sup">2</span>. Additional chemotherapeutic agents included: anthracyclines, carboplatin, cytostatic antibiotics, folic acid derivatives, methylhydrazine, nitrogen mustard analogs, podophyllotoxin derivatives, pyrimidine analogs, and vinca alkaloids. Granisetron hydrochloride injection doses of 10 and 40 mcg/kg were superior to 2 mcg/kg in preventing cisplatin-induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, but 40 mcg/kg was not significantly superior to 10 mcg/kg (see Table 4).<br><br><a name="table6"></a><table width="85%">
<caption><span>Table 4 Prevention of Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>-Single-Day High-Dose Cisplatin Therapy<span class="Sup">1</span></span></caption>
<col align="left" valign="top" width="41%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="13%">
<thead>
<tr class="First">
<th class="Lrule" align="left"></th>
<th class="Botrule Lrule" align="center" colspan="3">Granisetron Hydrochloride Injection <br>(mcg/kg)</th>
<th class="Botrule Lrule Rrule" align="center" colspan="2">P-Value<br>(vs. 2 mcg/kg)</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th class="Lrule Rrule" align="center">2</th>
<th class="Rrule" align="center">10</th>
<th class="Rrule" align="center">40</th>
<th class="Rrule" align="center">10</th>
<th class="Rrule" align="center">40</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Number of Patients</td>
<td class="Lrule Rrule" align="center">52</td>
<td class="Rrule" align="center">52</td>
<td class="Rrule" align="center">53</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">Response Over 24 Hours</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">Complete Response<span class="Sup">2</span>
</td>
<td class="Lrule Rrule" align="center">31%</td>
<td class="Rrule" align="center">62%</td>
<td class="Rrule" align="center">68%</td>
<td class="Rrule" align="center">&lt;0.002</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr>
<td class="Lrule" align="left">No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule Rrule" align="center">38%</td>
<td class="Rrule" align="center">65%</td>
<td class="Rrule" align="center">74%</td>
<td class="Rrule" align="center">&lt;0.001</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">No More Than Mild <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule Rrule" align="center">58%</td>
<td class="Rrule" align="center">75%</td>
<td class="Rrule" align="center">79%</td>
<td class="Rrule" align="center">NS</td>
<td class="Rrule" align="center">0.007</td>
</tr>
</tbody>
</table>
<span class="Sup">1</span>Cisplatin administration began within 10 minutes of granisetron hydrochloride injection infusion and continued for 2.6 hours (mean). Mean cisplatin doses were 96 to 99 mg/m<span class="Sup">2</span>. <br><span class="Sup">2</span>No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and no moderate or severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. <br><br>Granisetron hydrochloride injection was also evaluated in a double-blind, randomized dose response study of 353 patients stratified for high (≥80 to 120 mg/m<span class="Sup">2</span>) or low (50 to 79 mg/m<span class="Sup">2</span>) cisplatin dose. Response rates of patients for both cisplatin strata are given in Table 5.<br><br><a name="table7"></a><table width="90%">
<caption><span>Table 5  Prevention of Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>-Single-Day High-Dose and Low-Dose Cisplatin Therapy<span class="Sup">1</span></span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="10%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="4">Granisetron Hydrochloride Injection <br>(mcg/kg)</th>
<th class="Botrule Rrule" align="center" colspan="3">P-Value<br>(vs. 5 mcg/kg)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">5</th>
<th class="Rrule" align="center">10</th>
<th class="Rrule" align="center">20</th>
<th class="Rrule" align="center">40</th>
<th class="Rrule" align="center">10</th>
<th class="Rrule" align="center">20</th>
<th class="Rrule" align="center">40</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold">High-Dose Cisplatin</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Number of Patients</td>
<td class="Rrule" align="center">40</td>
<td class="Rrule" align="center">49</td>
<td class="Rrule" align="center">48</td>
<td class="Rrule" align="center">47</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Response Over 24 Hours</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Complete Response<span class="Sup">2</span>
</td>
<td class="Rrule" align="center">18%</td>
<td class="Rrule" align="center">41%</td>
<td class="Rrule" align="center">40%</td>
<td class="Rrule" align="center">47%</td>
<td class="Rrule" align="center">0.018</td>
<td class="Rrule" align="center">0.025</td>
<td class="Rrule" align="center">0.004</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">28%</td>
<td class="Rrule" align="center">47%</td>
<td class="Rrule" align="center">44%</td>
<td class="Rrule" align="center">53%</td>
<td class="Rrule" align="center">NS</td>
<td class="Rrule" align="center">NS</td>
<td class="Rrule" align="center">0.016</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  No <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">15%</td>
<td class="Rrule" align="center">35%</td>
<td class="Rrule" align="center">38%</td>
<td class="Rrule" align="center">43%</td>
<td class="Rrule" align="center">0.036</td>
<td class="Rrule" align="center">0.019</td>
<td class="Rrule" align="center">0.005</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Low-Dose Cisplatin</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Number of Patients</td>
<td class="Rrule" align="center">42</td>
<td class="Rrule" align="center">41</td>
<td class="Rrule" align="center">40</td>
<td class="Rrule" align="center">46</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Response Over 24 Hours</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Complete Response<span class="Sup">2</span>
</td>
<td class="Rrule" align="center">29%</td>
<td class="Rrule" align="center">56%</td>
<td class="Rrule" align="center">58%</td>
<td class="Rrule" align="center">41%</td>
<td class="Rrule" align="center">0.012</td>
<td class="Rrule" align="center">0.009</td>
<td class="Rrule" align="center">NS</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">36%</td>
<td class="Rrule" align="center">63%</td>
<td class="Rrule" align="center">65%</td>
<td class="Rrule" align="center">43%</td>
<td class="Rrule" align="center">0.012</td>
<td class="Rrule" align="center">0.008</td>
<td class="Rrule" align="center">NS</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  No <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">29%</td>
<td class="Rrule" align="center">56%</td>
<td class="Rrule" align="center">38%</td>
<td class="Rrule" align="center">33%</td>
<td class="Rrule" align="center">0.012</td>
<td class="Rrule" align="center">NS</td>
<td class="Rrule" align="center">NS</td>
</tr>
</tbody>
</table>
<span class="Sup">1</span>Cisplatin administration began within 10 minutes of granisetron hydrochloride injection infusion and continued for 2 hours (mean). Mean cisplatin doses were 64 and 98 mg/m<span class="Sup">2</span> for low and high strata.<br><span class="Sup">2</span>No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and no use of rescue antiemetic.<br><br>For both the low and high cisplatin strata, the 10, 20, and 40 mcg/kg doses were more effective than the 5 mcg/kg dose in preventing <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> within 24 hours of chemotherapy administration. The 10 mcg/kg dose was at least as effective as the higher doses.<br><br><span class="Italics">Moderately Emetogenic Chemotherapy</span><br>Granisetron hydrochloride injection, 40 mcg/kg, was compared with the combination of chlorpromazine (50 to 200 mg/24 hours) and dexamethasone (12 mg) in patients treated with moderately emetogenic chemotherapy, including primarily carboplatin &gt;300 mg/m<span class="Sup">2</span>, cisplatin 20 to 50 mg/m<span class="Sup">2</span> and cyclophosphamide &gt;600 mg/m<span class="Sup">2</span>. Granisetron hydrochloride injection was superior to the chlorpromazine regimen in preventing <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (see Table 6).<br><br><a name="table8"></a><table width="85%">
<caption><span>Table 6  Prevention of Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>-Single-Day Moderately Emetogenic Chemotherapy</span></caption>
<col align="left" valign="top" width="44%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="18%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Granisetron Hydrochloride Injection </th>
<th class="Rrule" align="center">Chlorpromazine<span class="Sup">1</span>
</th>
<th class="Rrule" align="center">P-Value</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">Number of Patients</td>
<td class="Rrule" align="center">133</td>
<td class="Rrule" align="center">133</td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Response Over 24 Hours</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Complete Response<span class="Sup">2</span>
</td>
<td class="Rrule" align="center">68%</td>
<td class="Rrule" align="center">47%</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">73%</td>
<td class="Rrule" align="center">53%</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">No More Than Mild <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">77%</td>
<td class="Rrule" align="center">59%</td>
<td class="Rrule" align="center">&lt;0.001</td>
</tr>
</tbody>
</table>
<span class="Sup">1</span>Patients also received dexamethasone, 12 mg.<br><span class="Sup">2</span>No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and no moderate or severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.<br><br>In other studies of moderately emetogenic chemotherapy, no significant difference in efficacy was found between granisetron hydrochloride injection doses of 40 mcg/kg and 160 mcg/kg.<br><br><span class="Underline">Repeat-Cycle Chemotherapy</span><br>In an uncontrolled trial, 512 cancer patients received granisetron hydrochloride injection, 40 mcg/kg, prophylactically, for two cycles of chemotherapy, 224 patients received it for at least four cycles, and 108 patients received it for at least six cycles. Granisetron hydrochloride injection efficacy remained relatively constant over the first six repeat cycles, with complete response rates (no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and no moderate or severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> in 24 hours) of 60% to 69%. No patients were studied for more than 15 cycles.<br><br><span class="Underline">Pediatric Studies</span><br>A randomized double-blind study evaluated the 24-hour response of 80 pediatric cancer patients (age 2 to 16 years) to granisetron hydrochloride injection 10, 20 or 40 mcg/kg. Patients were treated with cisplatin ≥60 mg/m<span class="Sup">2</span>, cytarabine ≥3 g/m<span class="Sup">2</span>, cyclophosphamide ≥1 g/m<span class="Sup">2</span> or nitrogen mustard ≥6 mg/m<span class="Sup">2</span> (see Table 7).<br><br><a name="table9"></a><table width="85%">
<caption><span>Table 7  Prevention of Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> in Pediatric Patients</span></caption>
<col align="left" valign="top" width="55%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="First">
<th class="Lrule" align="left"></th>
<th class="Botrule Lrule Rrule" align="center" colspan="3">Granisetron Hydrochloride Injection Dose (mcg/kg)</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left"></th>
<th class="Lrule Rrule" align="center">10</th>
<th class="Rrule" align="center">20</th>
<th class="Rrule" align="center">40</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Number of Patients</td>
<td class="Lrule Rrule" align="center">29</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">25</td>
</tr>
<tr>
<td class="Lrule" align="left">Median Number of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> Episodes</td>
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Complete Response Over 24 Hours<span class="Sup">1</span>
</td>
<td class="Lrule Rrule" align="center">21%</td>
<td class="Rrule" align="center">31%</td>
<td class="Rrule" align="center">32%</td>
</tr>
</tbody>
</table>
<span class="Sup">1</span>No <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and no moderate or severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.<br><br>A second pediatric study compared granisetron hydrochloride injection 20 mcg/kg to chlorpromazine plus dexamethasone in 88 patients treated with ifosfamide ≥3 g/m<span class="Sup">2</span>/day for two or three days. Granisetron hydrochloride injection was administered on each day of ifosfamide treatment. At 24 hours, 22% of granisetron hydrochloride injection patients achieved complete response (no <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and no moderate or severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> in 24 hours) compared with 10% on the chlorpromazine regimen. The median number of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> episodes with granisetron hydrochloride injection was 1.5; with chlorpromazine it was 7.0.<br>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="d3ba64f8-1278-44f1-8f8d-2664b4b08cc6"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>Granisetron hydrochloride injection USP, 1 mg/mL (free base), is supplied in 4 mL Multi-Use Vials. Contains preservative.<br>NDC 64679-661-02 (package of 1 Multi-Use Vial)<br><br>Store at 20°-25°C (68°-77°F). [See USP Controlled Room Temperature]<br><br>Once the multi-use vial is penetrated, its contents should be used within 30 days.<br><br>Do not freeze. Protect from light.<br>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="c42b0659-3fca-4a13-ae04-df3fb778a3ba"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>Patients should be informed that the most common adverse reactions for the indication of chemotherapy induced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (see Table 1).<br><br>Patients should be advised of the risk of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> if they have a prior <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to a class of antiemetics known as 5-HT<span class="Sub">3</span> receptor antagonists.<br><br>Electrocardiogram changes (QT prolongation) have been reported with the use of granisetron hydrochloride injection. Patients should be cautioned about the use of this drug if they have heart problems or take medications for heart problems.<br><br>Patients should be informed that granisetron hydrochloride injection, USP 1 mg/mL contains methylparaben and propylparaben.<br><br><span class="Bold">Manufactured by:<br></span>Wockhardt Limited <br>Mumbai, India.<br><br><span class="Bold">Distributed by:</span><br>Wockhardt USA LLC.<br>20 Waterview Blvd.<br>Parsippany, NJ 07054<br>USA.<br><br>Rev.080811</div>
<div class="Section" data-sectionCode="51945-4">
<a name="bebb007f-e801-41ce-a409-bc7dc72b81ec"></a><a name="section-16"></a><p></p>
<div class="Figure"><img alt="Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=af68579f-c863-4535-94af-a4126b43c182&amp;name=Granisetron%204%20mg_Label.jpg"></div>
<br><div class="Figure"><img alt="Mono Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=af68579f-c863-4535-94af-a4126b43c182&amp;name=Granisetron%204%20mg_Mono%20Carton.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GRANISETRON HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">granisetron hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55648-661</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GRANISETRON HYDROCHLORIDE</strong> (GRANISETRON) </td>
<td class="formItem">GRANISETRON</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55648-661-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">4 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078565</td>
<td class="formItem">06/30/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>WOCKHARDT LIMITED
							(650069115)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">WOCKHARDT LIMITED</td>
<td class="formItem"></td>
<td class="formItem">676257570</td>
<td class="formItem">manufacture</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e6ecd37b-72e8-48e2-b8ec-d4637c4d44a3</div>
<div>Set id: af68579f-c863-4535-94af-a4126b43c182</div>
<div>Version: 2</div>
<div>Effective Time: 20111220</div>
</div>
</div> <div class="DistributorName">WOCKHARDT LIMITED</div></p>
</body></html>
